 All of the shares in the offering are to be sold by Bellerophon. Bellerophon also intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent 15 of the number of shares of common stock offered in the public offering at the public offering price, less underwriting discounts and commissions. Bellerophon expects to use the net proceeds from this offering, together with its existing cash and cash equivalents, for funding its ongoing clinical trials, for working capital and general corporate purposes. 